Therapeutic Inhalation of Hydrogen Gas for Alzheimer’s Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study.
Hirohisa Ono, Yoji Nishijima, Shigeo Ohta · Pharmaceuticals (Basel, Switzerland) · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 8 patients with AD, the mean individual ADAS-cog change showed significant improvement after 6 months of H₂ treatment (-4.1) vs. untreated patients (+2.6). These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 8 patients with AD. The mean individual ADAS-cog change showed significant improvement after 6 months of H₂ treatment (-4.1) vs. untreated patients (+2.6).
What the Researchers Studied
The researchers studied 8 patients with AD. The study used a human clinical study. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 3% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 3% source-reported H₂ gas concentration; reported treatment duration: 6 months. The mean individual ADAS-cog change showed significant improvement after 6 months of H₂ treatment (-4.1) vs. untreated patients (+2.6).
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for Alzheimer's disease and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 8 patients with AD. The reported sample size was 8. The study used a human clinical study. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 3% source-reported H₂ gas concentration. The reported treatment duration was 6 months.
Limitations and Safety
Reported limitations: The improvement by ADAS-cog and DTI assessments were maintained during the follow-up after 6 months (significantly) or 1 year (non-significantly). Despite these limitations, the researchers propose that H₂ inhalation is a candidate for the disease-modifying treatment of AD, as the effects of H₂ inhalation is striking.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.